The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): Results of a retrospective cohort study of the OMIT Bretagne and Pays de la Loire.
F. Grude
No relevant relationships to disclose
M. Campone
No relevant relationships to disclose
J. Frenel
No relevant relationships to disclose
P. Soulie
No relevant relationships to disclose
E. Vauleon
No relevant relationships to disclose
Y. Hadjarab
No relevant relationships to disclose
G. Ganem
No relevant relationships to disclose
F. Denis
No relevant relationships to disclose
J. Egreteau
No relevant relationships to disclose
A. Lortholary
No relevant relationships to disclose
M. Porneuf
No relevant relationships to disclose
H. Simon
No relevant relationships to disclose
P. Dam Hieu
No relevant relationships to disclose
V. Klein
No relevant relationships to disclose
B. Dominique
No relevant relationships to disclose
P. Deguiral
No relevant relationships to disclose
H. Desclos
No relevant relationships to disclose
P. Menei
No relevant relationships to disclose
S. Traoré
No relevant relationships to disclose